Abstract
Budgetary pressures within health care systems have led many health care providers to consider the switching of patients on long term anti hypertensive medication to agents with the lowest acquisition price. The long term success of this strategy hinges on price differentials remaining stable, an assumption that may not be valid in drug classes where patent expiry times vary. The treatment of hypertension using angiotensin receptor blockers (ARBs) represents just such a case. The present study, therefore, modelled the 5-year cost consequences of treatment based on losartan, candesartan, valsartan and irbesartan, based on expected patent expiry dates. A Markov model was constructed, applying dose-specific blood-pressure lowering and costs to a cohort of uncontrolled mild-moderate hypertensive patients and assessing the anticipated cost of treatment over a 5 year period. A probabilistic approach was adopted to account for between-patient and between-treatment differences. For both undiscounted and discounted models, a losartan-based regimen represents the least costly option of the four agents tested. Median (IQR) discounted expenditure per patient for each agent was: losartan: pound 506 ( pound 441- pound 650), candesartan: poun...Continue Reading
References
Jul 15, 1998·Clinical Therapeutics·S OparilJ A Witcher
May 13, 1999·Clinical Therapeutics·T Bunt
May 23, 2000·American Journal of Hypertension·P R ConlinA M Bunt
Dec 8, 2000·Clinical Therapeutics·A J ManolisR D Smith
Jun 20, 2001·Pharmacy World & Science : PWS·H EnlundM Korhonen
Oct 6, 2001·The Journal of Clinical Hypertension·S OparilJ Neutel
Apr 9, 2002·Lancet·Björn DahlöfUNKNOWN LIFE Study Group
Apr 26, 2003·Journal of Hypertension·Hans LithellUNKNOWN SCOPE Study Group
Jun 23, 2004·Lancet·Stevo JuliusUNKNOWN VALUE trial group
Aug 18, 2004·Journal of Hypertension·Boris L G Van WijkAnthonius de Boer
Oct 8, 2004·The Journal of Clinical Hypertension·C Ventika S Ram
Feb 24, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jean-Philippe BaguetPascal Auquier
Jun 9, 2005·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Eugenia Ch YiannakopoulouTheodoros D Mountokalakis
Jan 19, 2007·International Journal of Clinical Practice·James C Moon, Richard G Bogle
Jan 19, 2007·International Journal of Clinical Practice·Rubin Minhas
Jan 19, 2007·International Journal of Clinical Practice·J A Usher-SmithM Kirby
Mar 8, 2007·The Journal of Clinical Hypertension·Thomas D GilesJ Findlay Walker
Oct 5, 2007·Clinical Drug Investigation·J P BaguetS Robitail